VISCHER has advised Nouscom AG on its EUR 120m Series D financing, the firm reported on 19 October 2026. Nouscom, a clinical-stage, cancer interception focused biotech developing next-generation immunotherapies, announced the closing of the oversubscribed EUR 120m (USD 135m) round.
The round was co-led by M Ventures and Revelation Partners alongside new investors Angelini Industries (through Angelini Investments), the European Investment Bank (through Aurea, its co-investment facility with Angelini Ventures) and Neva SGR (Intesa Sanpaolo Group). According to the firm, Nouscom’s existing international life sciences investors also participated in the round.
Chambers and Co. since 2004.
The VISCHER team included Matthias Staehelin (Partner, Corporate/M&A), Luzius Zumstein (Managing Associate, Corporate/M&A) and Lucas Sturzenegger (Associate, Corporate/M&A), as well as Nadia Tarolli (Partner, Tax) and Michelle Bruni (Managing Associate, Tax).
For detailed information, as well as the picture copyright, please see the law firm’s original article here: https://www.vischer.com/en/knowledge/news/vischer-advises-nouscom-ag-on-its-eur-120m-series-d-financing/
